Watchlist Price Alert

Standard BioTools Inc. (LAB)

NASDAQ: LAB · Real-Time Price · USD

1.07

-0.08 (-6.96%)

At close: May 06, 2025, 3:59 PM

1.07

0.00%

After-hours: May 06, 2025, 07:56 PM EDT

-6.96% (1D)

Bid	0.81
Market Cap	405.52M
Revenue (ttm)	174.43M
Net Income (ttm)	-138.88M
EPS (ttm)	-0.52
PE Ratio (ttm)	-2.06
Forward PE	-12.72
Analyst	Hold

Ask	1.07
Volume	1,495,166
Avg. Volume (20D)	1,631,683
Open	1.12
Previous Close	1.15
Day's Range	1.06 - 1.15
52-Week Range	0.97 - 2.74
Beta	1.80

About LAB

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immu...

Sector Healthcare

IPO Date Feb 10, 2011

Employees 814

Stock Exchange NASDAQ

Ticker Symbol LAB

Website https://www.fluidigm.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for LAB stock is "Hold." The 12-month stock price forecast is $2.5, which is an increase of 133.64% from the latest price.

Stock Forecasts

Earnings Surprise

New

Standard BioTools has released their quartely earnings on May 6, 2025:

Revenue of $40.8M exceeds estimates by $700K, with -10.41% YoY decline.

EPS of -0.07 misses estimates by -0.03, with 74.07% YoY growth.

Why Price Moved

3 months ago

+26.38%

Standard BioTools shares are trading higher after ... Unlock content with Pro Subscription

9 months ago

-36.61%

Standard BioTools shares are trading lower after the company reported worse-than-expected Q2 financial results and cut FY24 revenue guidance below estimates. The company announced CFO Jeffery Black will resign.

News

23 hours ago · seekingalpha.com

Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript

Standard BioTools Inc. (NASDAQ:LAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants John Graziano - VP of IR Michael Egholm - President & CEO Alex Kim - CFO Conference Ca...

1 day ago · zacks.com

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago.

2 months ago · seekingalpha.com

Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript

Standard BioTools Inc. (NASDAQ:LAB ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CF...